Randomized controlled trials are the gold standard for evaluating the safety and efficacy of new therapeutics, but researchers often struggle to recruit sufficient patients to complete their studies, especially when treating rare diseases. External control groups that are compiled with existing patient data from previously conducted clinical trials can replace a study’s traditional control group. Because external control groups must be properly designed, researchers combine cutting-edge technologies, including artificial intelligence (AI) and data analytics, to assess large patient datasets.
Download this technology review from Medidata to learn
- How researchers integrate AI and data analytics to enhance clinical trials
- The benefits of external control arms
- How to design hybrid clinical trials by combining internal and external control groups